Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Given Consensus Rating of “Buy” by Brokerages

Shares of Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) have been given an average rating of “Buy” by the five research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $15.3333.

A number of brokerages have recently issued reports on RADX. Weiss Ratings restated a “sell (e+)” rating on shares of Radiopharm Theranostics in a research note on Wednesday, October 8th. Wall Street Zen cut shares of Radiopharm Theranostics to a “strong sell” rating in a research note on Friday. Finally, B. Riley restated a “buy” rating and set a $16.00 price target (up previously from $13.00) on shares of Radiopharm Theranostics in a research note on Tuesday, December 16th.

Institutional Trading of Radiopharm Theranostics

An institutional investor recently raised its position in Radiopharm Theranostics stock. PNC Financial Services Group Inc. grew its holdings in Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) by 100.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,000 shares of the company’s stock after acquiring an additional 8,000 shares during the quarter. PNC Financial Services Group Inc. owned 0.20% of Radiopharm Theranostics worth $88,000 at the end of the most recent reporting period.

Radiopharm Theranostics Price Performance

Shares of RADX stock opened at $4.93 on Friday. The stock’s 50 day simple moving average is $5.02 and its 200 day simple moving average is $5.32. Radiopharm Theranostics has a twelve month low of $3.50 and a twelve month high of $16.25.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.